SomaLogic (NASDAQ:SLGC – Get Rating) is one of 41 public companies in the "Commercial physical research" industry, but how does it contrast to its competitors? We will compare SomaLogic to similar businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, valuation, dividends and earnings.

Profitability

This table compares SomaLogic and its competitors' net margins, return on equity and return on assets.

Volatility and Risk

SomaLogic has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, SomaLogic's competitors have a beta of 5.23, meaning that their average stock price is 423% more volatile than the S&P 500.

Insider and Institutional Ownership

Analyst Recommendations

This is a summary of recent recommendations for SomaLogic and its competitors, as reported by MarketBeat.

SomaLogic currently has a consensus target price of $12.20, suggesting a potential upside of 221.90%. As a group, "Commercial physical research" companies have a potential upside of 40.51%. Given SomaLogic's stronger consensus rating and higher probable upside, analysts clearly believe SomaLogic is more favorable than its competitors.

Valuation & Earnings

This table compares SomaLogic and its competitors gross revenue, earnings per share (EPS) and valuation.

SomaLogic's competitors have higher revenue and earnings than SomaLogic. SomaLogic is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

SomaLogic beats its competitors on 7 of the 13 factors compared.

SomaLogic Company Profile

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.